DOCSLIB.ORG

Gold Standard Drug Monographs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gold Standard Drug Monographs Gold Standard Drug Monographs Drug Name A Thru Z A Thru Z Advantage A Thru Z Select Abacavir Abacavir; Lamivudine, 3TC Abacavir; Lamivudine, 3TC; Zidovudine, ZDV Abarelix Abatacept Abciximab Abetimus Abiraterone AbobotulinumtoxinA Absorbable Gelatin Sponge Acamprosate Acarbose Acebutolol Acerflex Acetaminophen Acetaminophen; Aspirin, ASA; Caffeine Acetaminophen; Brompheniramine; Dextromethorphan; Pseudoephedrine Acetaminophen; Brompheniramine; Pseudoephedrine Acetaminophen; Butalbital Acetaminophen; Butalbital; Caffeine Acetaminophen; Butalbital; Caffeine; Codeine Acetaminophen; Caffeine Acetaminophen; Caffeine; Chlorpheniramine; Hydrocodone; Phenylephrine Acetaminophen; Caffeine; Dihydrocodeine Acetaminophen; Caffeine; Magnesium Salicylate; Phenyltoloxamine Acetaminophen; Caffeine; Phenyltoloxamine; Salicylamide Acetaminophen; Chlorpheniramine Acetaminophen; Chlorpheniramine; Dextromethorphan Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine Acetaminophen; Chlorpheniramine; Phenylephrine Acetaminophen; Chlorpheniramine; Phenylephrine; Phenyltoloxamine Acetaminophen; Chlorpheniramine; Pseudoephedrine Acetaminophen; Clemastine; Pseudoephedrine Acetaminophen; Codeine Acetaminophen; Dexbrompheniramine; Pseudoephedrine Acetaminophen; Dextromethorphan Acetaminophen; Dextromethorphan; Doxylamine Acetaminophen; Dextromethorphan; Doxylamine; Pseudoephedrine Acetaminophen; Dextromethorphan; Guaifenesin; Phenylephrine Acetaminophen; Dextromethorphan; Guaifenesin; Pseudoephedrine Acetaminophen; Dextromethorphan; Phenylephrine Acetaminophen; Dextromethorphan; Pseudoephedrine Acetaminophen; Dichloralphenazone; Isometheptene Acetaminophen; Diphenhydramine Acetaminophen; Diphenhydramine; Pseudoephedrine Acetaminophen; Guaifenesin; Phenylephrine Acetaminophen; Hydrocodone Acetaminophen; Melatonin Acetaminophen; Oxycodone Acetaminophen; Pamabrom Acetaminophen; Pamabrom; Pyrilamine Acetaminophen; Pentazocine Acetaminophen; Phenyltoloxamine Acetaminophen; Propoxyphene Acetaminophen; Pseudoephedrine Acetaminophen; Tramadol Acetazolamide Acetic Acid, Glacial Acetic Acid; Hydrocortisone Acetic Acid; Oxyquinoline; Ricinoleic Acid Acetohexamide Acetohydroxamic Acid Acetophenazine Acetylcholine Chloride Acetylcysteine Acidophilus with Pectin Acidulated Phosphate Fluoride Acitretin Acrivastine; Pseudoephedrine Acyclovir Acyclovir; Hydrocortisone Adalimumab Adapalene Adapalene; Benzoyl Peroxide Adefovir ADEKs ADEKs Drops Adenosine Adenovirus vaccine Ado-Trastuzumab emtansine Advanced NatalCare Advanced-RF NatalCare Advera Afatinib Aflibercept A-Free Prenatal Agalsidase Alfa Agalsidase Beta Airborne Effervescent Health Formula Airborne Jr. Effervescent Health Formula Airborne Sore Throat Gummi Lozenges Albendazole Albumin Albuterol Albuterol; Ipratropium Alcaftadine Alclometasone Aldesleukin, IL-2 Alefacept Alemtuzumab Alendronate Alendronate; Cholecalciferol Alfentanil Alfimeprase Alfuzosin Alglucerase Alglucosidase alfa Alicaforsen Aliminase Aliskiren Aliskiren; Amlodipine Aliskiren; Amlodipine; Hydrochlorothiazide, HCTZ Aliskiren; Hydrochlorothiazide, HCTZ Aliskiren; Valsartan Alitretinoin Alkavite Allbee C-800 AllBee Plus Vitamin C Allopurinol Almotriptan Aloe Polysaccharide; Iodoquinol Alogliptin Alogliptin; Metformin Alosetron Alpha lipoic acid Alpha-1-proteinase Inhibitor Alprazolam Alprostadil Alteplase, tPA Altretamine Aluminum Acetate, Burow's Solution Aluminum Chloride Aluminum Hydroxide Aluminum Hydroxide; Magnesium Carbonate Aluminum Hydroxide; Magnesium Hydroxide Aluminum Hydroxide; Magnesium Hydroxide; Simethicone Aluminum Hydroxide; Magnesium Trisilicate Alvimopan Amantadine Ambenonium Chloride Ambrisentan Amcinonide Amediplase Amifostine Amikacin Amiloride Amiloride; Hydrochlorothiazide, HCTZ Aminate Fe Aminobenzoate Potassium Aminocaproic Acid Aminoglutethimide Aminolevulinic Acid Aminosalicylate sodium, Aminosalicylic acid Aminosyn 10% Aminosyn 3.5% Aminosyn 3.5% M Aminosyn 5% Aminosyn 5% Sulfite-Free Aminosyn 7% Aminosyn 7% with Electrolytes Aminosyn 7% with Electrolytes Sulfite-Free Aminosyn 8.5% Aminosyn 8.5% Sulfite-Free Aminosyn 8.5% with Electrolytes Sulfite-Free Aminosyn II 10% Sulfite-Free Aminosyn II 10% with Electrolytes Aminosyn II 3.5% Aminosyn II 5% Aminosyn II 7% Aminosyn II 8.5% Aminosyn 10% Sulfite-Free Aminosyn 3.5% M Sulfite-Free Aminosyn 3.5% Sulfite-Free Aminosyn 7% Sulfite-Free Aminosyn 8.5% with Electrolytes Aminosyn -HBC 7% Aminosyn -HBC 7% Sulfite-Free Aminosyn II Aminosyn II 10% Aminosyn II 3.5% in Dextrose 25% Aminosyn II 8.5% Sulfite-Free Aminosyn -PF 10% Aminosyn -RF 5.2% Aminosyn-PF 7% Sulfite-Free Amiodarone Amiprilose Amitriptyline Amitriptyline; Chlordiazepoxide Amlexanox Amlodipine Amlodipine; Atorvastatin Amlodipine; Benazepril Amlodipine; Hydrochlorothiazide, HCTZ; Olmesartan Amlodipine; Hydrochlorothiazide, HCTZ; Valsartan Amlodipine; Olmesartan Amlodipine; Telmisartan Amlodipine; Valsartan Ammonium Chloride Ammonium Lactate Amobarbital Amoxapine Amoxicillin Amoxicillin; Clarithromycin; Lansoprazole Amoxicillin; Clavulanic Acid Amphetamine Amphetamine; Dextroamphetamine Amphotericin B Amphotericin B cholesteryl sulfate complex (ABCD) Amphotericin B lipid complex (ABLC) Amphotericin B liposomal (LAmB) Ampicillin Ampicillin; Sulbactam Amprenavir Amsacrine Amyl Nitrite Amylase; Cellulase; Lipase; Protease Anagrelide Anakinra Anastrozole Ancestim Ancrod Androstenedione Androvite Anemagen Anemagen OB Anemagen FA Anidulafungin Anisindione Anistreplase, APSAC Annamycin Antazoline; Naphazoline Anthralin Anthrax Vaccine, Adsorbed Anti-Gastrin Vaccine Antihemophilic Factor, AHF, Factor VIII Anti-inhibitor Coagulant Complex Antipyrine; Benzocaine Antipyrine; Benzocaine; Phenylephrine Antipyrine; Benzocaine; U-Polycosanol 410 Antithrombin III Antithymocyte Globulin Apatate Apatate Forte Apomorphine Apraclonidine Aprepitant, Fosaprepitant Aprobarbital Aprotinin Ardeparin Arformoterol Argatroban Arginine Arimoclomol Aripiprazole Armodafinil Arsenic Trioxide Artemether Artemether; Lumefantrine Artesunate Articaine; Epinephrine Artificial Tears Ascocid -ISO-pH Vitamin C Powder Ascocid-500 D Ascocid-ISO-pH Vitamin C Ascorbic Acid, Vitamin C Asenapine Asoprisnil Asparaginase Erwinia chrysanthemi Aspirin, ASA Aspirin, ASA; Aluminum Hydroxide; Calcium Carbonate; Magnesium Hydroxide Aspirin, ASA; Butalbital; Caffeine Aspirin, ASA; Butalbital; Caffeine; Codeine Aspirin, ASA; Caffeine Aspirin, ASA; Caffeine; Dihydrocodeine Aspirin, ASA; Caffeine; Orphenadrine Aspirin, ASA; Caffeine; Propoxyphene Aspirin, ASA; Caffeine; Salicylamide Aspirin, ASA; Calcium Carbonate; Magnesium Oxide; Magnesium Carbonate Aspirin, ASA; Carisoprodol Aspirin, ASA; Carisoprodol; Codeine Aspirin, ASA; Citric Acid; Sodium Bicarbonate Aspirin, ASA; Codeine Aspirin, ASA; Diphenhydramine Aspirin, ASA; Dipyridamole Aspirin, ASA; Hydrocodone Aspirin, ASA; Meprobamate Aspirin, ASA; Methocarbamol Aspirin, ASA; Oxycodone Aspirin, ASA; Pentazocine Aspirin, ASA; Pravastatin Astemizole Astragalus, Astragalus membranaceus Atazanavir Atenolol Atenolol; Chlorthalidone Atomoxetine Atorvastatin Atorvastatin; Ezetimibe Atosiban Atovaquone Atovaquone; Proguanil Atracurium Atrasentan Atropine Atropine; Benzoic Acid; Hyoscyamine; Methenamine; Methylene Blue; Phenyl Salicylate Atropine; Difenoxin Atropine; Diphenoxylate Atropine; Edrophonium Atropine; Hyoscyamine; Phenobarbital; Scopolamine Atropine; Pralidoxime Attapulgite Atvogen Auranofin Aurothioglucose Avanafil Avian Influenza A (H5N1) Virus Vaccine Axitinib Azacitidine Azatadine Azatadine; Pseudoephedrine Azathioprine Azelaic Acid Azelastine Azilsartan Azilsartan; Chlorthalidone Azimilide Azithromycin Aztreonam B C With Folic Acid Plus B Complex with C and B-12 Injection B-50 Baby Vitamin Drops Baby Vitamin with Iron Bacampicillin Bacillus Calmette-Guerin Live, BCG Bacillus Calmette-Guerin Vaccine, BCG Bacitracin Bacitracin; Hydrocortisone; Neomycin; Polymyxin B Bacitracin; Neomycin; Polymyxin B Bacitracin; Polymyxin B Baclofen Bacmin Balanced Salt Solution, BSS Balsalazide Barium Sulfate Basiliximab Bazedoxifene BCAD 2 B-Complex B-Complex and B-12 B-Complex and C B-Complex with Vitamin B-12 Becaplermin, rh-PDGF Beclomethasone Bedaquiline BEELITH Belatacept Belimumab Belladonna Alkaloids; Ergotamine; Phenobarbital Belladonna; Butabarbital Belladonna; Caffeine; Ergotamine; Pentobarbital Belladonna; Kaolin; Paregoric; Pectin Belladonna; Opium Benazepril Benazepril; Hydrochlorothiazide, HCTZ Bendamustine Bendroflumethiazide Bendroflumethiazide; Nadolol Benoxinate; Fluorescein Bentoquatam Benzalkonium Chloride Benzalkonium Chloride; Benzocaine Benzalkonium Chloride; Benzocaine; Zinc Chloride Benzimidavir Benzocaine Benzocaine; Butamben; Tetracaine Benzocaine; Cetylpyridinium Chloride; Menthol; Tannic Acid Benzocaine; Chloroxylenol; Hydrocortisone Acetate Benzoin Tincture, Compound Benzoin Tincture Benzonatate Benzoyl Peroxide Benzoyl Peroxide; Clindamycin Benzoyl Peroxide; Erythromycin Benzoyl Peroxide; Hydrocortisone Benzoyl Peroxide; Sulfur Benzphetamine Benztropine Benzyl Alcohol Benzyl Alcohol; Pramoxine Bepotastine Bepridil Beractant Besifloxacin Beta-Carotene Beta-Glucan, Recombinant Betaine Betamethasone Betamethasone; Calcipotriene Betamethasone; Clotrimazole Betaxolol Bethanechol Bevacizumab Bevitamel Bexarotene Bicalutamide Bifeprunox Bilberry, Vaccinium myrtillus Bimatoprost Bios Life 2 Biotin Biotin Forte Biotin Forte Extra Strength Biperiden Bisacodyl Bismuth Subcitrate Potassium; Metronidazole; Tetracycline Bismuth
Load more

Recommended publications
  • Endothelin System and Therapeutic Application of Endothelin Receptor
    xperim ACCESS Freely available online & E en OPEN l ta a l ic P in h l a C r m f o a c l a o n l o r g u y o J Journal of ISSN: 2161-1459 Clinical & Experimental Pharmacology Research Article Endothelin System and Therapeutic Application of Endothelin Receptor Antagonists Abebe Basazn Mekuria, Zemene Demelash Kifle*, Mohammedbrhan Abdelwuhab Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia ABSTRACT Endothelin is a 21 amino acid molecule endogenous potent vasoconstrictor peptide. Endothelin is synthesized in vascular endothelial and smooth muscle cells, as well as in neural, renal, pulmonic, and inflammatory cells. It acts through a seven transmembrane endothelin receptor A (ETA) and endothelin receptor B (ETB) receptors belongs to G protein-coupled rhodopsin-type receptor superfamily. This peptide involved in pathogenesis of cardiovascular disorder like (heart failure, arterial hypertension, myocardial infraction and atherosclerosis), renal failure, pulmonary arterial hypertension and it also involved in pathogenesis of cancer. Potentially endothelin receptor antagonist helps the treatment of the above disorder. Currently, there are a lot of trails both per-clinical and clinical on endothelin antagonist for various cardiovascular, pulmonary and cancer disorder. Some are approved by FAD for the treatment. These agents are including both selective and non-selective endothelin receptor antagonist (ETA/B). Currently, Bosentan, Ambrisentan, and Macitentan approved
    [Show full text]
  • Abnormal Uterine Bleeding: Strategies for Management”
    PRE-CONGRESS COURSE 4 SIG Endometriosis & Endometrium “Abnormal uterine bleeding: strategies for management” CONTENTS Program overview p. 1 Speakers’ contributions • Abnormalities of menstrual bleeding: getting our terminologies right - I. Fraser (AUS) p. 3 • Abnormal uterine bleeding: the patient perspective - P. Warner (UK) p. 13 • Optimising strategies for evaluation and management of abnormal uterine bleeding - A. Prentice (UK) p. 32 • Unscheduled bleeding with exogenous hormone administration – P. Rogers (AUS) p. 33 • Strategies to control; endometrial bleeding - D. Archer (USA) p. 46 • Local mechanisms responsible for endometrial bleeding - H. Critchley (UK) p. 49 • Is there a role for selective progesterone receptor modulators in management of uterine bleeding? - K. Chwalisz (USA) p. 61 • Should menstruation be optional? – Health benefits of amenorrhoea – D. Baird (UK) p. 72 PRE-CONGRESS COURSE 4 - PROGRAMME SIG Endometriosis & Endometrium Abnormal uterine bleeding: strategies for management Course co-ordinators: H. Critchley (UK) & Th. D’Hooghe (B) Course description: Problematic uterine bleeding impairs quality of life for many women and often involves invasive treatments and significant cost. Agreement is needed on terminology and defi nitions in order to facilitate the establishment of multi-centre clinical trials evaluating the strategies for management. Contemporary management also requires an understanding of the patient’s perspective of her complaint and an understanding of acceptability to women of the available modes of investigation and treatment options. Optimal therapies will only be possible with a detailed understanding of the mechanisms involved in endometrial bleeding including unscheduled bleeding with exogenous hormone administration. Novel therapies need to be evaluated in the context of potential health benefits from therapies that reduce the number of menstrual cycles experienced by women.
    [Show full text]
  • Practice Parameters for the Treatment of Patients with Dominantly Inherited Colorectal Cancer
    Practice Parameters For The Treatment Of Patients With Dominantly Inherited Colorectal Cancer Diseases of the Colon & Rectum 2003;46(8):1001-1012 Prepared by: The Standards Task Force The American Society of Colon and Rectal Surgeons James Church, MD; Clifford Simmang, MD; On Behalf of the Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons is dedicated to assuring high quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The standards committee is composed of Society members who are chosen because they have demonstrated expertise in the specialty of colon and rectal surgery. This Committee was created in order to lead international efforts in defining quality care for conditions related to the colon, rectum, and anus. This is accompanied by developing Clinical Practice Guidelines based on the best available evidence. These guidelines are inclusive, and not prescriptive. Their purpose is to provide information on which decisions can be made, rather than dictate a specific form of treatment. These guidelines are intended for the use of all practitioners, health care workers, and patients who desire information about the management of the conditions addressed by the topics covered in these guidelines. Practice Parameters for the Treatment of Patients With Dominantly Inherited Colorectal Cancer Inherited colorectal cancer includes two main syndromes in which predisposition to the disease is based on a germline mutation that may be transmitted from parent to child.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,692,728 B2 Weipert Et Al
    USOO6692728B2 (12) United States Patent (10) Patent No.: US 6,692,728 B2 Weipert et al. (45) Date of Patent: Feb. 17, 2004 (54) POLYESTERS BASED ON HYDROXY FATTY (52) U.S. Cl. ......................... 424/59; 424/497; 424/489; ACDS AND LOWER HYDROXY ALKYL 424/70.11; 424/78.37; 424/78.08; 514/785; ACDS AND USES THEREOF 560/171; 560/172; 560/176; 560/183; 525/400 (58) Field of Search .......................... 424/59, 497, 489, (75) Inventors: Paul David Weipert, High Point, NC 424/70.11, 78.37; 514/785; 560/172,176, (US); Bharat B. Desai, Spartanburg, 183; 525/400 SC (US) (73) Assignee: Ethox Chemicals LLC, Greenville, SC ") References Cited (US) U.S. PATENT DOCUMENTS ( c: ) Notice: Subject to any disclaimer, the term of this 5,502,116 A 3/1996 Noda ......................... 525/415 patent is extended or adjusted under 35 5,614,576 A * 3/1997 Rutherford et al. ......... 524/270 U.S.C. 154(b) by 0 days. 5,851,937 A * 12/1998 Wu et al. ................... 442/394 * cited by examiner (21) Appl. No.: 10/388,426 (22) Filed: Mar 17, 2003 Primary Examiner Sabiha Qazi 9 (74) Attorney, Agent, or Firm-Isaac A. Angres (65) Prior Publication Data (57) ABSTRACT US 2003/0175222 A1 Sep. 18, 2003 The present invention provides biodegradable polyesters Related U.S. Application Data based on lower hydroxy acids and hydroxy fatty acids. The resulting polyesters are useful as cosmetic vehicles for (62) Division of application No. 09/805,894, filed on Mar. 15, Sunscreens, skin lotions and by themselves are also useful as 2001, now Pat.
    [Show full text]
  • Symptomatic Pharmacotherapy in ALS: Data Analysis from a Platform-Based Medication Management Programme
    PostScript J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2020-322938 on 21 April 2020. Downloaded from LETTER during the observation. Riluzole was ALS were provided with a mean number the drug most commonly used (93% of 3.2 symptomatic drugs. However, of patients; n=2219). Symptomatic the number of drugs per patient varied Symptomatic pharmacotherapy drugs were assorted to pharmacological substantially (figure 1D). Furthermore, in ALS: data analysis from a domains and to the attainment of treat- we identified an increasing number of ment goals (figure 1B). An overview prescribed drugs per patient in correla- platform- based medication and ranking of symptomatic drugs are tion to advanced stages of King’s clinical management programme summarised in the online supplementary stages of ALS (figure 1C).4 file 2. Based on the number of patients who received the drug, the following top INTRODUCTION 10 symptomatic medicines were identi- DISCUSSION Although symptomatic medicines fied (in decreasing order): mirtazapine, The symptomatic medication was anal- constitute an important intervention ipratropium bromide, pirenzepine, ysed at specialised ALS centres in in amyotrophic lateral sclerosis (ALS), citalopram, lorazepam, baclofen, metam- Germany collaborating on multidisci- few systematic investigations into drug izole, quinine, fentanyl and tetrahydro- plinary managed care. Data assessment management have been reported so far.1 cannabinol:cannabidiol. Patients with was facilitated by the common use of Furthermore, symptomatic pharmaco- therapy is constantly evolving with an increasing number of drugs being used. Therefore, more detailed information on drug prescription must be obtained to monitor the current standards of care, identify potential shortcomings in drug management and elucidate progress in symptomatic pharmacotherapy.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Neuroactive Insecticides: Targets, Selectivity, Resistance, and Secondary Effects
    EN58CH06-Casida ARI 5 December 2012 8:11 Neuroactive Insecticides: Targets, Selectivity, Resistance, and Secondary Effects John E. Casida1,∗ and Kathleen A. Durkin2 1Environmental Chemistry and Toxicology Laboratory, Department of Environmental Science, Policy, and Management, 2Molecular Graphics and Computational Facility, College of Chemistry, University of California, Berkeley, California 94720; email: [email protected], [email protected] Annu. Rev. Entomol. 2013. 58:99–117 Keywords The Annual Review of Entomology is online at acetylcholinesterase, calcium channels, GABAA receptor, nicotinic ento.annualreviews.org receptor, secondary targets, sodium channel This article’s doi: 10.1146/annurev-ento-120811-153645 Abstract Copyright c 2013 by Annual Reviews. Neuroactive insecticides are the principal means of protecting crops, people, All rights reserved livestock, and pets from pest insect attack and disease transmission. Cur- ∗ Corresponding author rently, the four major nerve targets are acetylcholinesterase for organophos- phates and methylcarbamates, the nicotinic acetylcholine receptor for neonicotinoids, the γ-aminobutyric acid receptor/chloride channel for by Public Health Information Access Project on 04/29/14. For personal use only. Annu. Rev. Entomol. 2013.58:99-117. Downloaded from www.annualreviews.org polychlorocyclohexanes and fiproles, and the voltage-gated sodium channel for pyrethroids and dichlorodiphenyltrichloroethane. Species selectivity and acquired resistance are attributable in part to structural differences in binding subsites, receptor subunit interfaces, or transmembrane regions. Additional targets are sites in the sodium channel (indoxacarb and metaflumizone), the glutamate-gated chloride channel (avermectins), the octopamine receptor (amitraz metabolite), and the calcium-activated calcium channel (diamides). Secondary toxic effects in mammals from off-target serine hydrolase inhibi- tion include organophosphate-induced delayed neuropathy and disruption of the cannabinoid system.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Effects of a Novel Estrogen-Free, Progesterone Receptor Modulator
    Edinburgh Research Explorer Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women Citation for published version: Brache, V, Sitruk-Ware, R, Williams, A, Blithe, D, Croxatto, H, Kumar, N, Kumar, S, Tsong, Y-Y, Sivin, I, Nath, A, Sussman, H, Cochon, L, Miranda, MJ, Reyes, V, Faundes, A & Mishell, D 2012, 'Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women', Contraception, vol. 85, no. 5, pp. 480-8. https://doi.org/10.1016/j.contraception.2011.10.003 Digital Object Identifier (DOI): 10.1016/j.contraception.2011.10.003 Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: Contraception Publisher Rights Statement: NIH Public access author manuscript General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 26. Sep. 2021 NIH Public Access Author Manuscript Contraception. Author manuscript; available in PMC 2013 May 01.
    [Show full text]
  • Acute Exposure to a Sublethal Dose of Imidacloprid and Coumaphos Enhances Olfactory Learning and Memory in the Honeybee Apis Mellifera
    Invert Neurosci DOI 10.1007/s10158-012-0144-7 ORIGINAL PAPER Acute exposure to a sublethal dose of imidacloprid and coumaphos enhances olfactory learning and memory in the honeybee Apis mellifera Sally M. Williamson • Daniel D. Baker • Geraldine A. Wright Received: 8 October 2012 / Accepted: 5 November 2012 Ó The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The decline of honeybees and other pollinating agricultural chemicals used to combat pests and fungi that insects is a current cause for concern. A major factor bees experience when they pollinate flowering crops or implicated in their decline is exposure to agricultural plants near agricultural land (Dainat et al. 2011; Neumann chemicals, in particular the neonicotinoid insecticides such and Carreck 2010; vanEngelsdorp et al. 2009). Systemic as imidacloprid. Honeybees are also subjected to additional insecticides, such as the neonicotinoids, are of particular chemical exposure when beekeepers treat hives with aca- concern as they persist in pollen and nectar long after ricides to combat the mite Varroa destructor. Here, we application (Rortais et al. 2005). Domesticated honeybees assess the effects of acute sublethal doses of the neoni- are also exposed to chemical acaricides administered by cotinoid imidacloprid, and the organophosphate acaricide beekeepers within the colony to control infestations of the coumaphos, on honey bee learning and memory. Imida- parasitic mite Varroa destructor (Rosenkranz et al. 2010). cloprid had little effect on performance in a six-trial It has been suggested that combined exposure to both olfactory conditioning assay, while coumaphos caused a pesticides and acaricides may be more toxic to bees than modest impairment.
    [Show full text]
  • St. John's Wort 2018
    ONLINE SERIES MONOGRAPHS The Scientific Foundation for Herbal Medicinal Products Hyperici herba St. John's Wort 2018 www.escop.com The Scientific Foundation for Herbal Medicinal Products HYPERICI HERBA St. John's Wort 2018 ESCOP Monographs were first published in loose-leaf form progressively from 1996 to 1999 as Fascicules 1-6, each of 10 monographs © ESCOP 1996, 1997, 1999 Second Edition, completely revised and expanded © ESCOP 2003 Second Edition, Supplement 2009 © ESCOP 2009 ONLINE SERIES ISBN 978-1-901964-61-5 Hyperici herba - St. John's Wort © ESCOP 2018 Published by the European Scientific Cooperative on Phytotherapy (ESCOP) Notaries House, Chapel Street, Exeter EX1 1EZ, United Kingdom www.escop.com All rights reserved Except for the purposes of private study, research, criticism or review no part of this text may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the written permission of the publisher. Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment may be required. In their efforts to provide information on the efficacy and safety of herbal drugs and herbal preparations, presented as a substantial overview together with summaries of relevant data, the authors of the material herein have consulted comprehensive sources believed to be reliable. However, in view of the possibility of human error by the authors or publisher of the work herein, or changes in medical knowledge, neither the authors nor the publisher, nor any other party involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for results obtained by the use of such information.
    [Show full text]
  • Mindy Goldman, MD Clinical Professor Dept
    Managing Menopause Medically and Naturally Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women’s Cancer Care Program, UCSF Breast Care Center and Women’s Health University of California, San Francisco I have nothing to disclose –Mindy Goldman, MD CASE STUDY 50 yr. old G2P2 peri-menopausal woman presents with complaints of significant night sweats interfering with her ability to sleep. She has mild hot flashes during the day. She has never had a bone mineral density test but her mother had a hip fracture at age 62 due to osteoporosis. Her 46 yr. old sister was diagnosed with breast cancer at age 43, treated with lumpectomy and radiation and currently is doing well. There is no other family history of cancer. Questions 1. Would you offer her MHT? 2. If yes, how long would you continue it? 3. If no, what would you offer for alternative treatments? 4. Would your treatment differ if you knew she had underlying heart disease? Is it safe? How long can I take it? What about Mymy Bones?bones? Will it protect my heart? MHT - 2015 What about my brain? Will I get breast cancer? What about my hot flashes? Menopausal Symptoms Hot flashes Night sweats Sleep disturbances Vaginal dryness/Sexual dysfunction Mood disturbances How to Treat Menopausal Symptoms Hormone therapy Alternatives to hormones Complementary and Integrative Techniques Prior to Women’s Health Initiative Hormone therapy primary treatment of menopausal hot flashes Few women would continue hormones past one year By 1990’s well known
    [Show full text]